NSE Detection Service

Neuron-specific enolase (NSE), also known as γ-enolase or enolase-2 (ENO2), is a type of enolase isozyme. NSE is associated with a variety of cancers. It is most commonly used for small cell lung cancer (SCLC) monitoring and treatment research, and is a biomarker suitable for lung cancer. Creative BioMart Biomarker provides customers with accurate, sensitive and specific cancer biomarker testing services, including B2M detection services. High-quality services, short turnaround time and reasonable prices can effectively help customers shorten the research cycle and reduce research costs.

NSE and Cancers

NSE is one of the three isozymes of enolase, mainly located in central and peripheral neurons and neuroendocrine cells. Enolase is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate, which includes three isozymes (α-enolase, β-enolase and γ- enolase). Studies have shown that enolase, pyruvate kinase and hexokinase may play a leading role in inflammatory metabolism and promote tumor proliferation under hypoxic conditions by enhancing glycolysis. Due to its localization characteristics, NSE is often used as a potential biomarker for neuronal death in central nervous system injury. In addition to this, it also has multiple functions in cancer progression. For example, NSE can promote cancer cell survival and proliferation by enhancing aerobic glycolysis. In cancer, the cell positioning of NSE can change and traffic to the cell surface to promote the migration of tumor cells by activating signaling pathways. NSE related research shows that its expression level is increased in a variety of cancers, especially in SCLC. NSE is considered to be a reliable biomarker for SCLC, and its expression level in serum is correlated with tumor size, disease stage, and tumor metastasis. Moreover, NSE has high specificity for SCLC. The detection of serum NSE helps to improve the early diagnosis efficiency of SCLC. At the same time, NSE has application prospects in disease monitoring and prediction of treatment response and survival rate of SCLC patients. Therefore, NSE is a useful SCLC biomarker, while the effectiveness of NSE as a biomarker in other cancers needs to be further studied.

space conformation of NSEFigure 1. space conformation of NSE (Xu, et al. 2019)

Application of NSE Detection

NSE can be used in biomarker researches about SCLC, non-small cell lung cancer, Merkel cell carcinoma, neuroendocrine tumours, neuroblastoma, etc.

Our Advantages

  • Guarantee high accuracy and sensitivity for NSE detection
  • Ensure high repeatability of NSE detection
  • Short turn-around time of detection service
  • Competitive price in the market of NSE detection services
  • Multiple technology platforms for B2M test services (ELISA, RIA, etc.)
  • Accept a wide range of sample types (plasma, serum, etc.)

Workflow of Biomarker Detection at Creative BioMart Biomarker

Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of NSE in each sample.

Workflow

At Creative BioMart Biomarker, we offer high-quality NSE detection service that ensuring the sensitivity and specificity of test results. You can also talk to our experts according to your certain requirement, and we will determine the final detection scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.

References:

  1. Boyd, M. T.; Vlatkovic, N. P53: a molecular marker for the detection of cancer. Expert Opinion on Medical Diagnostics. 2008, 2(9): 1013-1024.
  2. Urso, L.; et al. Critical review about MDM2 in cancer: possible role in malignant mesothelioma and implications for treatment. Critical Reviews in Oncology/Hematology. 2015, 97(8428): 220-230.
  3. Xu, C. M.; et al. Multifunctional neuron-specific enolase: its role in lung diseases. Bioscience Reports. 2019. 39(11): BSR20192732.

Menu

Contact Us

Subscribe

Enter your email here to subscribe